# Genmab (GMAB) — Analyst Forecast

GMAB · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/gmab/forecast

## Analyst consensus

| Consensus | Buy | Hold | Sell | Analysts |
| --- | --- | --- | --- | --- |
| Buy | 25 | 3 | 0 | 28 |

## Price target

| Low | Average | High | Analysts |
| --- | --- | --- | --- |
| $43.00 | $49.00 | $58.00 | 4 |

Last price $37.82 (as of Oct 16, 2026).

## Recent analyst ratings

| Date | Firm | Action | Rating | Price target |
| --- | --- | --- | --- | --- |
| Oct 7, 2026 | HC Wainwright & Co. | Maintained | Buy | $50.00 |
| Oct 7, 2026 | Truist Securities | Maintained | Buy | $45.00 |
| Oct 7, 2026 | Guggenheim | Maintained | Buy | $58.00 |
| Oct 5, 2026 | Guggenheim | Maintained | Buy | $54.00 |
| Sep 14, 2026 | HC Wainwright & Co. | Maintained | Buy | $40.00 |
| Aug 7, 2026 | Guggenheim | Maintained | Buy | $42.00 |
| Jul 22, 2026 | TD Cowen | Upgraded | Hold → Buy | $43.00 |
| Jul 2, 2026 | HC Wainwright & Co. | Maintained | Buy | $40.00 |
| Jun 23, 2026 | HC Wainwright & Co. | Maintained | Buy | $38.00 |
| Apr 30, 2026 | HC Wainwright & Co. | Maintained | Buy | $38.00 |
| Mar 27, 2026 | Wolfe Research | Initiated Coverage | Outperform | $32.00 |
| Mar 2, 2026 | Wells Fargo | Initiated Coverage | Overweight | $40.00 |
| Feb 23, 2026 | Guggenheim | Maintained | Buy | $40.00 |
| Feb 18, 2026 | HC Wainwright & Co. | Maintained | Buy | $40.00 |
| Feb 17, 2026 | Jefferies | Maintained | Buy | $41.50 |
| Feb 16, 2026 | Morgan Stanley | Maintained | Equal-Weight | $34.00 |
| Jan 28, 2026 | HC Wainwright & Co. | Maintained | Buy | $39.00 |
| Jan 20, 2026 | HC Wainwright & Co. | Maintained | Buy | $39.00 |
| Nov 10, 2025 | HC Wainwright & Co. | Maintained | Buy | $41.00 |
| Nov 7, 2025 | Truist Securities | Maintained | Buy | $48.00 |

## Frequently Asked Questions

### What is the price target for GMAB stock?

The average 12-month analyst price target for Genmab (GMAB) is $49.00, with a high estimate of $58.00 and a low of $43.00, across 4 analysts.

### Is GMAB a buy, sell, or hold?

Analysts covering Genmab currently average a Buy rating: 25 buy, 3 hold and 0 sell, from 28 analysts. Ratings reflect analyst opinion, not investment advice.

### What upside do analysts see for GMAB?

The average price target of $49.00 implies 29.56% upside from the last price of $37.82.

### What is the latest analyst rating on GMAB?

On Oct 7, 2026, HC Wainwright & Co. maintained Genmab at Buy with a price target of $50.00.

---

Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).